https://charts.traderzeitung.de/phases/US0008991046
string(1449) "{"isin":"US0008991046","name":"ADMA Biologics Inc","stock_id":7873057,"generated_at":"2026-10-06 17:32:00","days":[{"date":"2026-10-02","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":10.03,"close_at":"2026-10-02 15:25:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":9.73,"close_at":"2026-10-02 21:59:00","complete":true,"perf_pct":-2.991},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":9.735,"close_at":"2026-10-02 22:00:00","complete":true,"perf_pct":0.0514}]},{"date":"2026-10-05","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":9.66,"close_at":"2026-10-05 14:46:00","complete":true,"perf_pct":-0.7704},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":10.115,"close_at":"2026-10-05 21:59:00","complete":true,"perf_pct":4.7101},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":10.12,"close_at":"2026-10-05 22:06:00","complete":true,"perf_pct":0.0494}]},{"date":"2026-10-06","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":10.33,"close_at":"2026-10-06 17:31:00","complete":false,"perf_pct":2.0751},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
ADMA Biologics Aktie News & Nachrichten

ADMA Biologics Aktie News & Nachrichten

[WKN: A12FAG | Symbol: ADMA]
Realtimekurs
   
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Stocks in Action USA: ADMA Biologics, Tesla und Boeing.

ADMA Biologics (ADMA) – Die Aktie des BioTechs Aktie erreicht 52-Wochen-Hoch nach FDA-Zulassung! ...

Rund 20 % höhere Ausbeute: Die FDA-Zulassung für den innovativen Produktionsprozess lässt Bio-Tech ADMA Biologics ausbrechen.

ADMA Biologics (ADMA) ist eine Leader-Aktie der letzten Quartale. Es handelt sich um ein biopharmazeutisches...

ADMA Biologics – Immunoglobin-Spezialist profitiert von starker Nachfrage bei BIVIGAM und ASCENIV

Geschäftstreiber: ADMA Biologics (ADMA) hat sich auf die Entwicklung und Herstellung von plasmabasierten...

ADMA Biologics: Eine attraktive Wachstumsaktie für Biotech-Investoren

ADMA konzentriert sich auf die Entwicklung und Vermarktung von Plasmaprodukten und zielt dabei in...

Starke Quartalszahlen und optimierte Plasma-Nutzung treiben Wachstum an

ADMA Biologics verzeichnet seit 2020 nahezu dreistellige Wachstumsraten und konnte im 2. Quartal 2024...

  • ‹
  • 1
  • ›
MT Newswires 05.08.2026 22:32 Uhr

-- Earnings Flash (ADMA) ADMA Biologics, Inc. meldet Q2-Umsatz von 124,4 Mio. $, gegenüber FactSet-Schätzung von 125,3 Mio. $

16:19 Uhr EDT, 05.08.2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provi